Skip to main content

Table 2 Risk factors predicting 30-day mortality

From: Persistent bacteremia predicts poor outcomes among neutropenic patients with carbapenem-resistant gram-negative bloodstream infections receiving appropriate therapy

Characteristics

Univariate analysis

Multivariable analysis

Hazards ratio (95% CI)

P value

Adjusted Hazards ratio (95% CI)

P value

Age

1.01 (0.99,1.02)

0.573

1 (0.98,1.02)

0.772

Male gender

1.19 (0.74,1.92)

0.463

1.4 (0.83,2.34)

0.207

Polymyxin E (colistin) resistance

0.96 (0.53,1.74)

0.904

  

Hematologic condition

 Acute myeloid leukemia

0.56 (0.30,1.04)

0.065

  

 Acute lymphoblastic

0.73 (0.38,1.40)

0.34

 Leukemia

0.74 (0.39,1.40)

0.353

 Other malignant conditions Benign

Reference

–

No recovery from neutropenia

5.42 (3.28,8.93)

 < 0.001

4.28 (2.53,7.23)

 < 0.001

Prolonged and profound neutropenia a

0.65 (0.37,1.13)

0.13

  

Transplant

0.67 (0.41,1.11)

0.121

  

Intensive care requirement

7.84 (3.39,18.12)

 < 0.001

3.12 (1.23,7.93)

0.017

Presence of septic shock

12.34 (4.5,33.88)

 < 0.001

4.42 (1.47,13.28)

0.008

Dialysis requirement

2.75 (1.57,4.81)

 < 0.001

1.68 (0.92,3.05)

0.091

Primary organism Klebsiella pneumoniae

0.87 (0.50,1.52)

0.625

  

Previous bacterial infections

1.06 (0.64,1.75)

0.818

  

Concomitant bacterial infections

1.6 (0.96,2.66)

0.069

  

Cytomegalovirus reactivationb

2.31 (0.78,6.85)

0.132

  

Source of bacteremia: Probable gut translocationc

0.89 (0.54,1.45)

0.639

  

Previous exposure to polymyxin

1.22 (0.75,1.96)

0.421

  

Previous exposure to carbapenem

0.99 (0.43,2.28)

0.983

  

Persistent bacteremia

2.15 (1.35,3.41)

0.001

1.74 (1.05,2.89)

0.031

Treatment details

 Ceftazidime-avibactam-based therapy

0.82 (0.41,1.63)

0.569

  

 Polymyxin with Ceftazidime-avibactam combination

0.61 (0.36,1.04)

0.067

 Avibactam combination

  

 Alternate agents

0.75 (0.23,2.41)

0.624

 Polymyxin based therapy

Reference

–

  

No appropriate empirical therapy receivedd

0.50 (0.28,0.89)

0.019

0.77 (0.42,1.41)

0.389

  1. Bold values represents significant risk factors after multivariable analysis
  2. aProlonged and profound Neutropenia is defined as absolute neutrophil count < 100 cells/mm3 and a duration of 7 days
  3. bCytomegalovirus reactivation- More than 1000 copies of cytomegalovirus present 7 days before or after bacterial isolation
  4. cOther sources include pulmonary sources (6), central line related (19), Skin and soft tissue infections (14) and other or unknown sources (7)
  5. dInappropriate empiric therapy was defined as receipt of agents without documented in vitro activity
Back to article page

Annals of Clinical Microbiology and Antimicrobials

ISSN: 1476-0711

Contact us